Literature DB >> 17914406

Protecting neurons from HIV-1 gp120-induced oxidant stress using both localized intracerebral and generalized intraventricular administration of antioxidant enzymes delivered by SV40-derived vectors.

J-P Louboutin1, L Agrawal, B A S Reyes, E J Van Bockstaele, D S Strayer.   

Abstract

Human immunodeficiency virus-1 (HIV-1) is the most frequent cause of dementia in adults under 40. We sought to use gene delivery to protect from HIV-1-related neuron loss. Because HIV-1 envelope (Env) gp120 elicits oxidant stress and apoptosis in cultured neurons, we established reproducible parameters of Env-mediated neurotoxicity in vivo, then tested neuroprotection using gene delivery of antioxidant enzymes. We injected 100-500 ng mul(-1)gp120 stereotaxically into rat caudate-putamens (CP) and assayed brains for apoptosis by terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling (TUNEL) 6-h to 14-day post-injection. Peak apoptosis occurred 1 day after injection of 250 and 500 ng microl(-1)gp120. TUNEL-positive cells mostly expressed neuronal markers (NeuroTrace), although some expressed CD68 and so were most likely microglial cells. Finally, we compared neuroprotection from gp120-induced apoptosis provided by localized and generalized intra-central nervous system (CNS) gene delivery. Recombinant SV40 vectors carrying Cu/Zn superoxide dismutase (SOD1) or glutathione peroxidase (GPx1) were injected into the CP, where gp120 was administered 4-24 weeks later. Alternatively, we inoculated the vector into the lateral ventricle (LV), with or without prior intraperitoneal (i.p.) administration of mannitol. Intracerebral injection of SV(SOD1) or SV(GPx1) significantly protected neurons from gp120-induced apoptosis throughout the 24-week study. Intraventricular vector administration protected from gp120 neurotoxicity comparably, particularly if preceded by mannitol i.p. Thus, HIV-1 gp120 is neurotoxic in vivo, and intracerebral or intra-ventricular administration of rSV40 vectors carrying antioxidant enzymes is neuroprotective. These findings suggest the potential utility of both localized and widespread gene delivery in treating neuroAIDS and other CNS diseases characterized by excessive oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17914406     DOI: 10.1038/sj.gt.3303030

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  20 in total

1.  Gene transfer to the cerebellum.

Authors:  Jean-Pierre Louboutin; Beverly A S Reyes; Elisabeth J Van Bockstaele; David S Strayer
Journal:  Cerebellum       Date:  2010-12       Impact factor: 3.847

2.  Efficient CNS gene delivery by intravenous injection.

Authors:  Jean-Pierre Louboutin; Alena A Chekmasova; Elena Marusich; J Roy Chowdhury; David S Strayer
Journal:  Nat Methods       Date:  2010-10-17       Impact factor: 28.547

Review 3.  Editorial neuroAIDS review.

Authors:  Paul Shapshak; Pandjassarame Kangueane; Robert K Fujimura; Deborah Commins; Francesco Chiappelli; Elyse Singer; Andrew J Levine; Alireza Minagar; Francis J Novembre; Charurut Somboonwit; Avindra Nath; John T Sinnott
Journal:  AIDS       Date:  2011-01-14       Impact factor: 4.177

4.  Quantitative diffusion tensor imaging tractography metrics are associated with cognitive performance among HIV-infected patients.

Authors:  David F Tate; Jared Conley; Robert H Paul; Kathryn Coop; Song Zhang; Wenjin Zhou; David H Laidlaw; Lynn E Taylor; Timothy Flanigan; Bradford Navia; Ronald Cohen; Karen Tashima
Journal:  Brain Imaging Behav       Date:  2010-01-19       Impact factor: 3.978

5.  Gene delivery of antioxidant enzymes inhibits human immunodeficiency virus type 1 gp120-induced expression of caspases.

Authors:  J-P Louboutin; L Agrawal; B A S Reyes; E J van Bockstaele; D S Strayer
Journal:  Neuroscience       Date:  2012-04-21       Impact factor: 3.590

6.  p53 as a retrovirus-induced oxidative stress modulator.

Authors:  Soo Jin Kim; Paul K Y Wong
Journal:  J Gen Virol       Date:  2014-09-24       Impact factor: 3.891

7.  HIV-1 gp120-induced injury to the blood-brain barrier: role of metalloproteinases 2 and 9 and relationship to oxidative stress.

Authors:  Jean-Pierre Louboutin; Lokesh Agrawal; Beverly A S Reyes; Elisabeth J Van Bockstaele; David S Strayer
Journal:  J Neuropathol Exp Neurol       Date:  2010-08       Impact factor: 3.685

8.  Role of CCR5 and its ligands in the control of vascular inflammation and leukocyte recruitment required for acute excitotoxic seizure induction and neural damage.

Authors:  Jean-Pierre Louboutin; Alena Chekmasova; Elena Marusich; Lokesh Agrawal; David S Strayer
Journal:  FASEB J       Date:  2010-10-12       Impact factor: 5.191

Review 9.  Large animal models of neurological disorders for gene therapy.

Authors:  Christine Gagliardi; Bruce A Bunnell
Journal:  ILAR J       Date:  2009

Review 10.  Apoptosis in animal models of virus-induced disease.

Authors:  Penny Clarke; Kenneth L Tyler
Journal:  Nat Rev Microbiol       Date:  2009-02       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.